30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Arrivent Biopharma Inc (AVBP)

Track

The most recent insider trading activity at Arrivent Biopharma Inc. occurred on December 10, 2025, with a significant sell transaction by HILLHOUSE INVESTMENT MANAGEMENT, LTD. Prior to this, on January 30, 2024, several buy transactions were recorded from entities including GORDON CARL L, ORBIMED ADVISORS LLC, HEALY JAMES, and HILLHOUSE INVESTMENT MANAGEMENT, LTD.
Stock chart
Ticker: AVBP Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
HILLHOUSE INVESTMENT MANAGEMENT, LTD.
1 sale — total 12,983,320 USD
Sale 10 Dec 2025
Value US$1,011,716.46 | Price 449.36 | Shares 40,435
Buy 30 Jan 2024
Value US$4,848,610.28 | Price 320.22 | Shares 20,100
Buy 30 Jan 2024
Value US$3,999,996.00 | Price 18.00 | Shares 222,222
Buy 30 Jan 2024
Value US$3,999,996.00 | Price 18.00 | Shares 222,222
Buy 30 Jan 2024
Value US$7,999,992.00 | Price 18.00 | Shares 444,444
Buy 30 Jan 2024
Value US$3,999,996.00 | Price 18.00 | Shares 222,222
Buy 30 Jan 2024
Value US$3,999,996.00 | Price 18.00 | Shares 222,222
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-02-03 2025-12-10 S Sale
1.6
HILLHOUSE INVESTMENT MANAGEMENT, LTD.
Large shareholder
40,435 +24.5%
449.36
US$1,011,716 		40,435 +24.5% 449.36 US$1,011,716
2024-02-01 2024-01-30 B Purchase
1.6
HILLHOUSE INVESTMENT MANAGEMENT, LTD.
Large shareholder
20,100 +33.1%
320.22
US$4,848,610 		20,100 +33.1% 320.22 US$4,848,610
2024-01-31 2024-01-30 B Purchase
1.5
GORDON CARL L
Non-Executive Director Large shareholder
63,795 -9.9%
258.54
US$4,094,982 		63,795 -9.9% 258.54 US$4,094,982
2024-01-31 2024-01-30 B Purchase
1.5
GORDON CARL L
Non-Executive Director Large shareholder
222,222 +17.2%
18.00
US$3,999,996 		222,222 +17.2% 18.00 US$3,999,996
2024-01-31 2024-01-30 B Purchase
2.9
HEALY JAMES
Non-Executive Director
444,444 +35.5%
18.00
US$7,999,992 		444,444 +35.5% 18.00 US$7,999,992
2024-01-31 2024-01-30 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
222,222 +17.2%
18.00
US$3,999,996 		222,222 +17.2% 18.00 US$3,999,996
2024-01-31 2024-01-30 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
222,222 +17.2%
18.00
US$3,999,996 		222,222 +17.2% 18.00 US$3,999,996
Explore more

More insider trading research around Arrivent Biopharma Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America